et al. Inhibition of eukaryotic initiation factor 3B suppresses proliferation and promotes apoptosis of chronic myeloid leukemia cells.
Introduction
Chronic myeloid leukemia (CML) is a hematopoietic stem cell (HSC) malignancy that results from the formation of the Philadelphia chromosome due to reciprocal chromosomal translocation t(9;22)(q34.12;q11.23), and it accounts for 15-20% of all leukemias. 1 Patients with CML need to be treated for life; moreover, the prognosis of patients with blastic transformation of CML is extremely poor. Thus, there is an unmet need to find better treatments for CML.
Eukaryotic initiation factors (eIFs) are a large family of proteins that regulate the rate-limiting step of protein synthesis in the initiation stage. 2 To date, numerous eIFs have been identified and several of them consist of multiple subunits that determine their functions. 3, 4 A growing number of studies illustrate that various eIFs are aberrantly expressed or activated in different types of human cancers. 5, 6 There is a growing interest in understanding the mechanisms of eIFs in modulating gene translation initiation and how they promote oncogenesis. Scientists have hypothesized that an increased rate of translation would affect the downstream mRNA synthesis and that a high level of eIFs could enhance the translation of these mRNAs. Preclinical studies have shown that overexpression of eIFs resulted in cells transforming into those with cancerous characteristics, as demonstrated by pervasive growth and increased proliferation. 7 The largest group of these eIFs, eukaryotic translation initiation factor 3 (eIF3), consists of 13 subunits (eIF3a through eIF3m) with a total molecular mass of 700 kDa, and plays an essential role in the initiation of translation. 8 eIF3 mediates several steps of the translation initiation pathway, which includes recruiting the eIF2-GTP-MET-tRNA (iMet) ternary complex and other eIFs to the 40S ribosomal subunit to form the 43S preinitiation complex, mRNA recruitment and subsequent scanning of the 5' untranslated region (UTR) and starting codon. 9 eIF3b has been verified to be overexpressed in colon, bladder and prostate cancers as well as in glioblastoma due to its impact on the cellular activity of cancer cells. [10] [11] [12] While several eIF proteins have been implicated in CML, 6, 7 there is no study in the literature exploring the correlation of eIF3b expression with cell proliferation and apoptosis in CML. Therefore, that is precisely the aim of the current study.
Material and methods

Sample collection and eIF3b mRNA expression
A total of 16 CML patients were enrolled in this study at the Department of Hematology of Yijishan Hospital, First Affiliated Hospital of Wannan Medical College, Wuhu, China, from January 2015 to March 2017. As controls, 16 age-and gender-matched non-malignant patients who had undergone bone marrow biopsy (12 thrombocytopenic purpura, 3 infectious diseases and 1 healthy donor) were enrolled. During the bone marrow biopsy, 2 mL of bone marrow sample was obtained from each participant; mononuclear cells were then isolated. This was followed by total RNA extraction and eIF3b mRNA was detected with quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). This study was approved by the Ethics Committee of Yijishan Hospital, First Affiliated Hospital of Wannan Medical College Hospital. The participants provided written informed consent. eIF3b expression in different leukemia cell lines TK-6, K562 and Jurkat cell lines were purchased from the Shanghai Institutes for Biological Science (Shanghai, China). After resuscitation, these cells were maintained in RPMI-1640 medium (Gibco, Carlsbad, USA) containing 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Corning, Lowell, USA) at 37°C with a humidified atmosphere of 5% CO 2 . Meanwhile, mononuclear cells were isolated from the bone marrow of 3 control subjects (patients without malignancies) and were defined as the control group. The expression of eIF3b mRNA was detected with qRT-PCR.
Detection of K562 cell transduction, proliferation and apoptosis
K562 cells were transduced with the lentivirus-anti-eIF3b vector (LVpGCSIL-004PSC2749-1; Shanghai Gemma, Shanghai, China) and identified as the sheI-F3b group (the sequences of anti-eIF3b: 5′-GCUACA-AGCUUGACAAGCAdTdT-3′ (F) and 5′-UGCUUGU-CAAGCUUGUAGCdTdT-3′ (R)); those transduced with an empty vector (psc3741, Shanghai Gemma) served as the control group (shCtrl group, irrelevant sequence). The level of fluorescence was observed under a fluorescence microscope; all transduction rates were more than 90%. Briefly, qRT-PCR, western blotting, CCK-8 and fluorescence-activated cell sorting (FACS) were used to examine the eIF3b mRNA level, protein level, cell proliferation, cell cycles, and apoptosis in the K562 cells. For western blot analysis, the total protein was adjusted into equal amounts and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Specific antibodies were used to detect each corresponding protein. The antibodies used for western blotting analysis are listed in Table 1 .
RNA extraction and qRT-PCR analysis
Total RNA samples from cells were extracted with TRIzol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. The extracted RNA was pretreated with RNase-free DNase, and 1 μg of RNA from each sample was used for cDNA synthesis with random hexamers (RNA to cDNA EcoDry ™ Premix; TAKA-RA, Kusatsu, Japan). The cDNA products were subjected to qRT-PCR with a SYBR FAST Mastermix kit (KAPA, Boston, USA). The following primer sequences were used: -eIF3b forward primer:
5'-CGGTGCCTTAGCGTTTGTG-3'; -eIF3b reverse primer:
5'-CGGTCCTTGTTGTTCTTCTGC-3'; -GAPDH forward primer:
5'-TGACTTCAACAGCGACACCCA-3'; -GAPDH reverse primer:
5'-CACCCTGTTGCTGTAGCCAAA-3'. The PCR amplification was performed as follows: 95°C for 5 min, followed by 40 cycles of 95°C for 4 s and 61°C for 30 s. The PCR amplification was performed in triplicate. The qRT-PCR results were calculated with the 2 -ΔΔ Ct method.
Western blot analysis
Western blotting was performed for the detection of eI-F3b and Bcl-2 expression. The total protein was extracted from cells lysed in RIPA buffer (Thermo Fisher Scientific, Waltham, USA) containing phosphatase and protease inhibitors. Then, 20 μg of protein samples were subjected to SDS-PAGE and transferred onto polyvinylidene fluoride membranes (Merck Millipore, Bedford, USA). After blocking with 5% skim milk for 2 h, the membranes were incubated with the corresponding primary antibodies overnight at 4°C. Then, the membranes were incubated with the appropriate HRP-conjugated secondary antibodies for 1 h at room temperature. The bands were visualized using an enhanced chemiluminescence (ECL) kit (Merck Millipore), followed by exposure to X-ray film. All of the antibodies used are listed in Table 1 .
CCK-8 assay
After transduction, cells coupled with CCK-8 dye were incubated with 5% CO 2 at 37°C. The proliferation was evaluated at timepoints of 4 h, 24 h, 48 h, 72 h, and 96 h. The plates were tested and the fluorescence value was read once a day with a microplate reader (Biotek, Winooski, USA). The fluorescence values of each of the 5 days were collected and analyzed to create a proliferation curve.
FACS analysis of cell cycle and apoptosis
For the analysis of the cell cycle, cells were collected 48 h after transduction. The cells were washed 3 times with phosphate-buffered saline (PBS) and fixed in 70% prechilled ethanol at 4°C for 1 h. The cells were then suspended in 500 μL of PBS combined with 50 μg/mL of propidium iodide (PI) and 100 μg/mL of ribonuclease, and incubated at 4°C for 30 min in the dark. A 300-mesh nylon net was used to filter and separate the aggregated cells. The cell cycle was analyzed with flow cytometry on a FACScan (BD Biosciences, East Rutheford, USA).
For the analysis of apoptosis, 48 h after transduction, the cells were collected and washed 3 times with PBS, then suspended in 100 μL of PBS; 1 μL of PI was added to the cell suspension, which was incubated at 4°C for 5 min in the dark. The cells stained with PI were detected using flow cytometry on a FACScan. The analysis was performed with a BD FACSCanto II flow cytometer and BD FACSDiva software v. 6.1.3 (BD Biosciences).
Caspase-3/7 activity analysis
Three days after transduction, cells were harvested for caspase-3/7 activity analysis using an Amplite ™ Colorimetric Caspase 3/7 Assay Kit (AAT Bioquest, Sunnyvale, USA). Caspase-3/7 activity was measured using 30 μg of lysate by detecting the chromophore p-nitroaniline, which was cleaved from the labeled substrate N-acetyl-Asp-Glu-Val-Asp p-nitroanilide.
Statistical methods
The statistical analysis was performed using SPSS software v. 22.0 (IBM Corp., Armonk, USA). Data was presented as mean ± standard deviation (SD). Comparisons between 2 groups were carried out with a t-test. A p-value <0.05 was considered statistically significant.
Results
Overexpression of eIF3b mRNA in CML
The results of qRT-PCR showed that the expression of eIF3b mRNA in the CML patients was higher than that of the control group (p < 0.01) (Fig. 1A) . In addition, eIF3b was found to be overexpressed in the TK-6 (p < 0.001), K562 (p < 0.001) and Jurkat (p < 0.05) CML cells when compared with normal control cells (mononuclear cells isolated from the bone marrow of healthy individuals, Fig. 1B ). shRNA inhibits eIF3b mRNA and protein expression
After transduction with lentivirus-anti-eIF3b or emptyvector lentivirus in the K562 cells for 3 days, the fluorescence expression was observed under a fluorescence microscope, which showed that the transduction efficiency of both was over 90% ( Fig. 2A) . After 3 days, the expression of eIF3b mRNA and protein had both decreased markedly in the sheIF3b group compared with the shCtrl group (Fig. 2B,C) .
Downregulation of eIF3b mRNA-inhibited proliferation of K562 cells
The CCK-8 assay showed no significant difference in baseline optical density (OD) between the sheIF3b and shCtrl groups. On days 3, 4 and 5 after transduction, the OD value of the sheIF3b group was lower than that of the shCtrl group (Fig. 3A,B) , a finding which suggests that the inhibition of eIF3b mRNA suppresses the proliferation of K562 cells. 
Effect of eIF3b gene downregulation on K562 cell cycles
Following transduction with shRNA lentivirus -on day 5 -the proportion of cells in the G1 (p < 0.01) and S phases (p < 0.05) of the sheIF3b group was lower than that of the shCtrl group, while the proportion of cells in the G2/M phase (p < 0.01) was higher than in the shCtrl group (Fig. 4A,B ).
Effect of eIF3b mRNA downregulation on the apoptosis of K562 cells
On day 5 after transduction, the total cell apoptosis percentage in the sheIF3b group was substantially higher than that of the shCtrl group (p < 0.01, Fig. 5A,B) . Caspase 3/7 activity in the sheIF3b group was remarkably higher (p < 0.01, Fig. 6A ) than that of the control group, and the expression of anti-apoptotic protein Bcl-2 was markedly lower in the sheIF3b group than in the shCrtl group (p < 0.01, Fig. 6B ), suggesting that eIF3b downregulation promoted the apoptosis of K562 cells.
Discussion
Chronic myeloid leukemia is a clonal HSC disorder resulting from a reciprocal translocation between the long arms of ch9 and ch22, t (9;22), which leads to the fusion of the ABL1 proto-oncogene from ch9 with the BCR housekeeping gene on ch22 to produce the BCR-ABL gene. 13 This fusion gene is transcribed into BCR-ABL1 mRNA and translated into the BCR-ABL protein, which initiates the progression of CML. 14, 15 Dysregulation of mRNA translation leads to the aberrant activation of cellular pathways that promote cell proliferation, invasion and progression of leukemia. The main function of eIFs is in the interaction between the ribosome and mRNA, which takes part in the initial process of protein synthesis, affecting cell cycle, growth and apoptosis. 16, 17 eIF3b, a member of the eIF3 complex, is reported to be overexpressed in various tumor cells and acts as an oncogene. A study indicated that eIF3b mRNA is abundantly expressed in colon cancer cells, and that the downregulation of eIF3b inhibits cell proliferation, reduces the number of cells in the G1 phase and increases the number of cells in the S/G2 phases, as well as promotes cell apoptosis. 8 Another study investigating the role of eIF3b in esophageal squamous cell carcinoma (ESCC) also revealed that eIF3b expression is much higher in ESCC tissues and ESCC cell lines, while a reduction in eIF3b suppresses cell proliferation and stimulates cell apoptosis through the regulation of the β-catenin signaling pathway. 18 In bladder and prostate cancer cells, eIF3b deletion decreases cell growth and represses the G1/S cell cycle transition by regulating cyclin A, E, Rb, and p27Kip1 protein expression -but not mRNA expression -and it reduces migration as well as interrupting the actin cytoskeleton and focal adhesions. 11 A recently published study showed that knockdown of eIF3b decreases cell viability and promotes apoptosis in osteosarcoma cells due to the regulation of tumor necrosis factor receptor superfamily member 21 (TNFRSF21). 19 These findings indicate that eIF3b is involved in tumor development and progression by acting as a cancer-promoting gene.
In clinical research, Wang et al. examined the expression of eIF3b mRNA in patients with bladder cancer and prostate cancer, and reported that eIF3b mRNA expression is much higher in cancer patients than in controls. Interestingly, they also discovered that eIF3b mRNA is positively correlated with tumor grade and could predict unfavorable survival. 9 However, the role of eIF3b in CML remains unclear. In this study, we found that eIF3b mRNA expression was higher in CML patients and CML cell lines than in the controls. Downregulation of eIF3b expression suppressed CML cell proliferation, decreased G1/Sphase cells and induced cell apoptosis, which was in line with the oncogenic role of eIF3b in other studies. Reduced eIF3b mRNA expression inhibits proliferation and promotes apoptosis in K562 cells. The possible explanations could be as follows: 1) eIF3b could activate the β-catenin signaling pathway, including the downstream target gene cyclin D1 and c-Myc, thus inducing cell proliferation and invasion, as well as inhibiting cell apoptosis and interfering with the cell cycle 18 or; 2) eIF3b is involved in protein synthesis and eIF3b depletion can globally inhibit protein synthesis, which affects the proliferation and apoptosis of cancer cells. 9 There were some limitations in this study. Firstly, the prognostic role of eIF3b expression in CML patients was not investigated. Secondly, we discovered the role of eIF3b in regulating CML cell proliferation and apoptosis, but the mechanism of how eIF3b affects cancer cell progression was not explored. This will be the focus of future research.
In conclusion, the downregulation of eIF3b inhibits proliferation and induces apoptosis in CML cells. 
